Antidiabetic effect of chebulic acid in streptozotocin induced diabetic rats
Narendra Silawat1*, Vipin Bihari Gupta2
1 Research Scholar, Faculty of Pharmaceutical Sciences, Jodhpur National University, Jodhpur (Rajasthan)
2 Director, B. R. Nahata College of Pharmacy, Mandsaur (Madhya Pradesh)
Ethanopharmacological relevance: Terminalia chebula is widely incorporated to treat diabetes and its complications; chebulic acid was used to prevent advanced glycation end products-induced endothelial cell dysfunction, however the antidiabetic effect of chebulic acid is questionable.
Aim of study: The present study was designed to investigate the effect of chebulic acid in streptozotocin induced diabetes in rats. Materials and methods: Chebulic acid (CA) was isolated from T. chebula. LD50 and acute toxicity studies of CA was done. Chebulic acid at doses of 25 and 50 mg/kg was administered to diabetic rats (STZ; 50 mg/kg i.p.). CA and glibenclamide (10 mg/kg) were administered for 28 days and various biochemical parameters were monitored in order to analyze antidiabetic effect.
Results: LD50 was found to be 251 mg/kg; 25 and 50 mg/kg dose were selected as no toxic symptoms were observed at both doses, except slight diarrhea. CA at both doses significantly increased glucose and sucrose tolerance. The statistical data indicated that CA significantly (p<0.001) reduced blood glucose level, glycosylated hemoglobulin, fructosamine, glucose 6 phosphate dehydrogenase, glucose 6 phosphatase, lactate dehydrogenase, glycogen phosphorylase, fructose 1,6 bisphosphatase, and urine glucose excretion. CA significantly decreased glycoprotein levels where as glycogen level, serum insulin, glycogen synthetase, and hexokinase were significantly increased.
Conclusion: CA significantly regulated hyperglycemia and could be a therapeutic agent for regulating several pharmacological targets for treatment or prevention of diabetes.
Antidiabetic; Chebulic acid; Glibenclamide; LD50; Streptozotocin